Here's What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $33 from $32 and maintained an Underweight rating on the shares. The firm stated that it refreshed its estimates on the stock and reviewed incremental pipeline progress after partner Vertex Pharmaceuticals recently reported fiscal Q4 Casgevy sales.

CRISPR Therapeutics AG (NASDAQ:CRSP) also received a rating update from JPMorgan on February 16. The firm cut the price target on the stock to $67 from $69 while maintaining an Overweight rating on the shares. It told investors that the company’s fiscal Q4 results came broadly in line with expectations, and that it looks forward to the company’s pipeline updates later this year.

The same day, Citi also adjusted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP), raising it to $80 from $77 and reaffirming a Buy rating on the shares. The firm stated that the company’s Casgevy revenue exceeded estimates in fiscal Q4, and that it sees CRISPR Therapeutics AG’s (NASDAQ:CRSP) clinical and preclinical updates in 2026 driving potential upside in the shares.

Headquartered in Zug, Switzerland, CRISPR Therapeutics AG (NASDAQ:CRSP) develops transformative gene-based medicines for serious diseases through its proprietary CRISPR/Cas9 platform. The CRISPR/Cas9 platform allows precise changes to genomic DNA by employing gene editing technology. The company’s product portfolio spans therapeutic programs across various disease areas, including oncology, rare diseases, regenerative medicine, etc.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.